(Reuters) – The generic drugmaker Akorn is facing a world of trouble. The German healthcare giant Fresenius, which received court approval last year to walk away from a $4.75 billion deal to …
More Why would allegedly defrauded Akorn investors want … more Akorn stock? Videos